VRTX241227C540000
- 3.76
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Jim Cramer on Vertex Pharmaceuticals Incporated (VRTX): 'This Is Hardly Down For The Year. I Think It Can Still Go Lower'
Analysts Are Bullish on Top Healthcare Stocks: Oruka Therapeutics (ORKA), Vertex Pharmaceuticals (VRTX)
Truist Financial Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $460
Will Vertex Pharmaceuticals Incorporated (VRTX) Make You Rich In 2025?
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
Top Stock Reports for T-Mobile, Toyota Motor & Vertex Pharmaceuticals
Vertex Pharmaceuticals Price Target Lowered to $460 From $550 at Truist
Truist has lowered the Vertex Target Price to 460 dollars.
Truist: lowered the Target Price of Vertex Pharmaceuticals from $550 to $460, maintaining a Buy rating. (Gelonghui)
A Quick Look at Today's Ratings for Vertex Pharmaceuticals(VRTX.US), With a Forecast Between $430 to $525
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek
Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst
Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday
RBC Capital Keeps Their Hold Rating on Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Price Target Raised to $430.00/Share From $426.00 by Scotiabank
Vertex Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
Vertex Pharmaceuticals (VRTX) Receives a Buy From Bank of America Securities
TD Cowen Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Is Maintained at Overweight by JP Morgan
JP Morgan Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $500